# AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)

> **NCT03028740** · PHASE3 · TERMINATED · sponsor: **Tobira Therapeutics, Inc.** · enrollment: 1778 (actual)

## Conditions studied

- Nonalcoholic Steatohepatitis

## Interventions

- **DRUG:** Placebo
- **DRUG:** Cenicriviroc

## Key facts

- **NCT ID:** NCT03028740
- **Lead sponsor:** Tobira Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-04-05
- **Primary completion:** 2021-01-12
- **Final completion:** 2021-03-09
- **Target enrollment:** 1778 (ACTUAL)
- **Why stopped:** This study was terminated early due to lack of efficacy based on the results of the planned interim analysis of Part 1 data.
- **Last updated:** 2022-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03028740

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03028740, "AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03028740. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*